A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutation
| Condition(s) | Non Small Cell Lung Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations. |
| Who can participate | Inclusion Criteria: * 1.Diagnosed as advanced non-small cell lung cancer * 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation Exclusion Criteria: * The patient is diagnosed with small cell lung cancer |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Yongchang Zhang |
| Locations | Changsha, Hunan, China; Changsha, Hunan, China |
| Start date | 2023-01-01 |
| NCT ID | NCT04777175 |
| Official listing | https://clinicaltrials.gov/study/NCT04777175 |